Back to EZorb Newsletter Index

In this issue:

1. Share Success: Letters From Readers
2. Research News: Focused Ultrasound Ablation Helpful for Parkinson’s
3. Useful Links
4. What Are Others Saying About EZorb and Marvlix?

Letter I: From Barbara M.
Received at Testimonial Submit Form Monday, May 8, 2023 at 2:31 PM PDT
(Unedited)

Hi, my name is Barbara M. I wish I could’ve got on EZorb 3 years ago when I initially developed heel spurs. I went through all the information on the website and was about to pull the trigger but my family was fiercely against it – they thought I was desperate and I shouldn’t trust the Internet.

The pain got worse over time. I was scared every time I had to get on my feet. Excluciating pain I cried and cried couldn’t take it anymore. I finally purchased EZorb don’t care about others’ opinion no more.

It really did get rid of my heel spurs it really worked! It took awhile because I am on my feet every day.

For years I had this pain and in about couple of months it was gone!

I have other friends starting to take the EZorb. Thank you so very much!

Letter II: From Brenda F., Michigan
Received at sharesuccess @ ezorbonline.com Sunday, April 16, 2023 at 8:47 AM PDT
(Unedited)

I've been taking ezorb for about 9 months now. I have osteoporosis and before taking foxomax I surfed the net and discovered ezorb. I’m so glad I did it.

I noticed a differance almost immediately. I can hardly wait to see my bone density count.

Thank you EZorb.

Brenda F., Michigan

Our newsletter reaches over 230,000 subscribers worldwide. Success stories you shared in the past have made a great impact on many people's life.

Please email your story to sharesuccess @ ezorbonline.com or simply post it to Testimonial Submit Form. Your personal information will never be revealed to the public.

Focused ultrasound ablation (FUSA) of the globus pallidus internus improved symptoms in a substantial proportion of people with Parkinson’s disease in a randomised trial, but it comes with side effects.

The treatment consisted of FUSA targeted to the globus pallidus internus contralateral to either the patient’s dominant side or the side with the greatest motor impairment.

In total, 65 of the patients who underwent FUSA and 22 who underwent a sham procedure completed the 3-month follow-up. During this time, 69% versus 32% of these groups met the criteria for a response, report Howard Eisenberg (University of Maryland, Baltimore, USA) and colleagues in The New England Journal of Medicine.

A response was regarded as an improvement in off-treatment motor impairment and/or on-treatment dyskinesias, specifically at least a 3-point improvement in off-medication Movement Disorders Society-Unified Parkinson’s Disease Rating Scale III for the treated side and in on-treatment Unified Dyskinesia Rating Scale, respectively.

In the active-treatment group, 29% had a response in motor symptoms only, 12% in dyskinesias only and 28% in both. In the sham group, 27% had a response in motor symptoms only and 5% in both motor symptoms and dyskinesia, with no participant recording an improvement in dyskinesias only.

Among 53 actively treated patients assessed after 12 months, 70% had a response. This included seven who had not had a response at month 3.

The most common treatment-related adverse events were dysarthria, gait disturbance and loss of taste, which each occurred in two patients. These were mostly mild and transient, but one patient had moderate dysarthria that persisted at the 1-year follow-up.

In a linked editorial, Anette Schrag (University College London, UK) says that “it is worth emphasizing that despite an incisionless procedure, FUSA of the globus pallidus internus is not risk-free.”

She also points out that “the degree of improvement was less than suggested by previous open-label studies”, that “not all patients derived a meaningful benefit from the intervention” and that only a third had improvements in both motor function and dyskinesias.

Schrag concludes: “The results of this trial are promising, but given the nonreversible nature of the intervention and the progressive nature of the disease, it will be important to establish whether improvements in motor complications are maintained over longer periods and whether treatment results in improved overall functioning and quality of life for patients.”

Original research was published in N Engl J Med 2023; 388.

EZorb - Frequently Asked Questions & Answers

EZorb Clinical Studies

Marvlix Benefits

Order Now

EZorb and Marvlix have restored confidence in thousands of men and women. It has brought happiness and healthy life to families around the world. Click here to read what people say about EZorb and Marvlix.

Back to EZorb Newsletter Index